Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Yinan Liu's publication output changed over time?
ScholarIQpublication output · 2014–2023
Output declined67% over the shown period — from 3 works in 2014 to 1 in 2023.
3
1
4
1
1
1
201420152016201820202023
What are the most-cited papers on Yinan Liu?
ScholarIQmost cited works
Dietary fiber intake and risk of type 2 diabetes: a dose–response analysis of prospective studies
Baodong Yao, Hong Fang, Wanghong Xu, Yujie Yan, Huilin Xu, Yinan Liu, Miao Mo, Hua Zhang, Yanping Zhao
European Journal of Epidemiology. 2014283 Citations
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Shang‐Gin Wu, Yinan Liu, Meng‐Feng Tsai, Yih‐Leong Chang, Chong‐Jen Yu, Pan‐Chyr Yang, James Chih‐Hsin Yang, Yueh‐Feng Wen, Jin‐Yuan Shih
Oncotarget. 2016237 CitationsOPEN ACCESS
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
Chao Lv, Wentao Fang, Nan Wu, Wenjie Jiao, Shidong Xu, Haitao Ma, Jia Wang, Rui Wang, Chunyu Ji, Shaolei Li, Yuzhao Wang, Yan Shi, Fangliang Lu, Yuquan Pei, Yinan Liu, Yue Yang
Lung Cancer. 2023115 CitationsOPEN ACCESS
IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer
Yinan Liu, Tzu‐Hua Chang, Meng‐Feng Tsai, Shang‐Gin Wu, Tzu‐Hsiu Tsai, Hsuan‐Yu Chen, Sung‐Liang Yu, James Chih‐Hsin Yang, Jin‐Yuan Shih
Oncotarget. 201588 CitationsOPEN ACCESS
Expression of inflammatory cytokines in serum and peritoneal fluid from patients with different stages of endometriosis
Yanyan Fan, Hongyu Chen, Wei Chen, Yinan Liu, Yan Fu, Lina Wang
S144560499. 201888 Citations
Related on ScholarIQ
Sun Yat-sen University
Institution
Dietary fiber intake and risk of type 2 diabetes: a dose–response analysis of prospective studies
Paper
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
Paper
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
Paper
IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer
Paper
Expression of inflammatory cytokines in serum and peritoneal fluid from patients with different stages of endometriosis
Paper